{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:45:29Z","timestamp":1768009529061,"version":"3.49.0"},"reference-count":29,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Urological cancer encompasses a diverse range of tumors, including bladder, prostate, renal, upper urinary tract, and germ cell tumors [...]<\/jats:p>","DOI":"10.3390\/ijms242115795","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:16:27Z","timestamp":1698750987000},"page":"15795","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4352-1784","authenticated-orcid":false,"given":"Vicen\u00e7","family":"Ruiz de Porras","sequence":"first","affiliation":[{"name":"CARE Program, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain"},{"name":"Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B\u00b7ARGO), 08916 Badalona, Spain"},{"name":"Grup de Recerca en Toxicologia (GRET), Unitat de Toxicologia, Departament de Farmacologia, Toxicologia i Qu\u00edmica Terap\u00e8utica, Facultat de Farm\u00e0cia i Ci\u00e8ncies de l\u2019Alimentaci\u00f3, Universitat de Barcelona, Avda. Joan XXIII s\/n, 08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Font","sequence":"additional","affiliation":[{"name":"CARE Program, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain"},{"name":"Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B\u00b7ARGO), 08916 Badalona, Spain"},{"name":"Medical Oncology Department, Catalan Institute of Oncology, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/cncr.34907","article-title":"Top advances of the year: Genitourinary cancer","volume":"129","author":"Young","year":"2023","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00262-023-03367-w","article-title":"Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial","volume":"72","author":"Shiota","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Andrzejczak, A., Tupikowski, K., Tomkiewicz, A., Malkiewicz, B., Ptaszkowski, K., Domin, A., Szydelko, T., and Karabon, L. (2023). The Variations\u2019 in Genes Encoding TIM-3 and Its Ligand, Galectin-9, Influence on ccRCC Risk and Prognosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032042"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/PPO.0000000000000477","article-title":"Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer","volume":"26","author":"Ravi","year":"2020","journal-title":"Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17588359221108685","DOI":"10.1177\/17588359221108685","article-title":"Evolving landscape of first-line combination therapy in advanced renal cancer: A systematic review","volume":"14","author":"Lalani","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zaccagnino, A., Vynnytska-Myronovska, B., Stockle, M., and Junker, K. (2023). An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065648"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kowalewski, A., Jaworski, D., Borowczak, J., Maniewski, M., Szczerbowski, K., Antosik, P., Durslewicz, J., Smolinska, M., Ligmanowska, J., and Grzanka, D. (2022). TOLLIP Protein Expression Predicts Unfavorable Outcome in Renal Cell Carcinoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314702"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"518225","DOI":"10.3389\/fphar.2020.518225","article-title":"Autophagy as a Vital Therapy Target for Renal Cell Carcinoma","volume":"11","author":"He","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ncrna.2022.02.004","article-title":"Long noncoding RNAs as promising biomarkers in cancer","volume":"7","author":"Beylerli","year":"2022","journal-title":"Noncoding RNA Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.omto.2021.08.003","article-title":"Comprehensive analysis of lncRNAs as biomarkers for diagnosis, prognosis, and treatment response in clear cell renal cell carcinoma","volume":"22","author":"Chao","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1122065","DOI":"10.3389\/fphar.2023.1122065","article-title":"The emerging role of long non-coding RNAs in renal cell carcinoma progression and clinical therapy via targeting metabolic regulation","volume":"14","author":"Gao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Rysz, J., Konecki, T., Franczyk, B., Lawinski, J., and Gluba-Brzozka, A. (2022). The Role of Long Noncoding RNA (lncRNAs) Biomarkers in Renal Cell Carcinoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010643"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"103795","DOI":"10.1016\/j.critrevonc.2022.103795","article-title":"Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions","volume":"178","author":"Pardo","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Perez-Montiel, M.D., Cerrato-Izaguirre, D., Sanchez-Perez, Y., Diaz-Chavez, J., Cortes-Gonzalez, C.C., Rubio, J.A., Jimenez-Rios, M.A., Herrera, L.A., Scavuzzo, A., and Meneses-Garcia, A. (2023). Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021092"},{"key":"ref_19","first-page":"e40962","article-title":"The Management of Bacillus Calmette-Guerin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article","volume":"15","author":"Kodera","year":"2023","journal-title":"Cureus"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"842182","DOI":"10.3389\/fonc.2022.842182","article-title":"Bacillus Calmette-Guerin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer","volume":"12","author":"Su","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Domingos-Pereira, S., Sathiyanadan, K., Polak, L., Haefliger, J.A., Schmittnaegel, M., Ries, C.H., Jichlinski, P., Roth, B., Derre, L., and Nardelli-Haefliger, D. (2022). Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010123"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tohi, Y., Taoka, R., Zhang, X., Matsuoka, Y., Yoshihara, A., Ibuki, E., Haba, R., Akimitsu, K., Izumori, K., and Kakehi, Y. (2022). Antitumor Effects of Orally Administered Rare Sugar D-Allose in Bladder Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126771"},{"key":"ref_23","first-page":"801","article-title":"D-allose: Molecular Pathways and Therapeutic Capacity in Cancer","volume":"16","author":"Khajeh","year":"2023","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.euf.2019.01.016","article-title":"Biological Evolution of Castration-resistant Prostate Cancer","volume":"5","author":"Davies","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40610-018-0095-9","article-title":"Epigenetic Regulation in Prostate Cancer Progression","volume":"4","author":"Ruggero","year":"2018","journal-title":"Curr. Mol. Biol. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pardo, J.C., Ruiz de Porras, V., Gil, J., Font, A., Puig-Domingo, M., and Jorda, M. (2022). Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer. Nutrients, 14.","DOI":"10.3390\/nu14040851"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Orea, M.J., Angulo, J.C., Gonzalez-Corpas, A., Echegaray, D., Marva, M., Lobo, M.V.T., Colas, B., and Ropero, S. (2023). Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010803"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sheta, M., Yoshida, K., Kanemoto, H., Calderwood, S.K., and Eguchi, T. (2023). Stress-Inducible SCAND Factors Suppress the Stress Response and Are Biomarkers for Enhanced Prognosis in Cancers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065168"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Eguchi, T., Csizmadia, E., Kawai, H., Sheta, M., Yoshida, K., Prince, T.L., Wegiel, B., and Calderwood, S.K. (2022). SCAND1 Reverses Epithelial-to-Mesenchymal Transition (EMT) and Suppresses Prostate Cancer Growth and Migration. Cells, 11.","DOI":"10.3390\/cells11243993"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/21\/15795\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:14:43Z","timestamp":1760130883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/21\/15795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":29,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ijms242115795"],"URL":"https:\/\/doi.org\/10.3390\/ijms242115795","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]}}}